Examples of 'romiplostim' in a sentence
Meaning of "romiplostim"
romiplostim (noun): A medication used in the treatment of certain blood disorders, such as immune thrombocytopenia. It works by stimulating the production of platelets in the body to help prevent excessive bleeding or bruising
Show more definitions
- A fusion protein analog of thrombopoietin.
How to use "romiplostim" in a sentence
Basic
Advanced
romiplostim
Advice on management of patients upon cessation of romiplostim.
Effects of romiplostim on red and white blood cells.
There are no data on excretion of romiplostim in human milk.
For romiplostim no clinical data on exposed pregnancies are available.
Nplate contains the active substance romiplostim.
The carcinogenic potential of romiplostim has not been evaluated.
Romiplostim had no observed effect on the fertility of rats.
It is not known whether romiplostim is present in human milk.
Romiplostim should be used with caution in these populations.
The incidence of neutralising antibodies to romiplostim in clinical trials.
Romiplostim serum levels appear inversely related to platelet counts.
It contains the active substance romiplostim.
Romiplostim and others are in development.
Injection site reactions were also related to romiplostim administration.
Romiplostim should not be used during pregnancy unless clearly necessary.
See also
Of action of reticulin deposition in response to romiplostim.
Romiplostim treatment is generally administered at weekly intervals via subcutaneous injection.
Thrombocytopenia is likely to reoccur upon discontinuation of treatment with romiplostim.
Micrograms of romiplostim.
The transient blast cell increases were reversible upon discontinuation of romiplostim.
Pharmacokinetics of romiplostim in patients with renal and hepatic impairment has not been investigated.
The active substance is romiplostim.
Romiplostim is not recommended during pregnancy and in women of childbearing potential not using contraception.
Total vial content of romiplostim.
Studies in animals have shown that romiplostim crossed the placenta and increased foetal platelet counts.
Loss of response to romiplostim.
Romiplostim has no amino acid sequence homology to endogenous TPO.
Monitoring of these parameters should be considered in patients treated with romiplostim.
The elimination of serum romiplostim is in part dependent on the TPO receptor on platelets.
In addition the events listed below have been deemed to be related to romiplostim treatment.
Romiplostim may induce the progression of existing haematological malignancies and myelodysplastic syndrome MDS.
In addition the reactions listed below have been deemed to be related to romiplostim treatment.
Romiplostim is also approved in the EU.
Guidelines for calculating individual patient dose and volume of romiplostim to administer.
Self-administration of romiplostim is not allowed for paediatric patients.
Clinical trials in adult ITP patients examined antibodies to romiplostim.
The mean duration of exposure to romiplostim in this study population was 50 weeks.
Romiplostim has been designed to attach to and stimulate the same targets ( receptors ) as thrombopoietin.
In clinical studies, antibodies to romiplostim were examined.
Approximately 4 months later, the patient tested negative for neutralising antibodies to romiplostim.
Therefore, the risk of potential carcinogenicity of romiplostim in humans remains unknown.
Romiplostim pharmacokinetics appear not affected by age, weight and gender to a clinically significant extent.
In clinical studies, treatment with romiplostim resulted in dose-dependent increases in platelet count.
The overall cost to the health-care system did not change with romiplostim treatment.
In clinical trials, treatment with romiplostim resulted in dose-dependent increases in platelet count.
In all developmental studies neutralising antibodies were formed, which may have inhibited romiplostim effects.
Romiplostim is indicated as a potential treatment for chronic idiopathic ( immune ) thrombocytopenic purpura ITP.
Bleeding, Serious bleeding can occur while taking romiplostim.
Pharmacokinetic data of romiplostim were collected from two studies in 21 paediatric subjects with ITP.
Carton containing 1 or 4 vials of romiplostim.
